(Q73047527)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9024121%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

review article

1 reference

title

Clinical uses of intravenous immunoglobulin in pregnancy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9024121%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

author name string

A L Clark

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9024121%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

S A Gall

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9024121%20AND%20SRC:MED&resulttype=core&format=json

American Journal of Obstetrics and Gynecology

31 October 2019

language of work or name

English

1 reference

inferred from

publication date

1 January 1997

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9024121%20AND%20SRC:MED&resulttype=core&format=json

American Journal of Obstetrics and Gynecology

31 October 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9024121%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

volume

176

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9024121%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

issue

1 Pt 1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9024121%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

page(s)

241-253

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9024121%20AND%20SRC:MED&resulttype=core&format=json

Recommendations for off-label use of intravenously administered immunoglobulin preparations. University Hospital Consortium Expert Panel for Off-Label Use of Polyvalent Intravenously Administered Immunoglobulin Preparations

31 October 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

Intravenous immunoglobulins as therapeutic agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

Clinical uses of intravenous immunoglobulins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

Manipulating the Immune System with Immune Globulin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

SUBCLASSES OF HUMAN GAMMA-2-GLOBULIN BASED ON DIFFERENCES IN THE HEAVY POLYPEPTIDE CHAINS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

Studies on human antibodies. VI. Selective variations in subgroup composition and genetic markers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

Methodology and safety considerations in the production of an intravenous immunoglobulin preparation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

Intravenous administration of human gamma-globulin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

Safety and toxicity of a new serum immunoglobulin G intravenous preparation, IGIV pH 4.25

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

Intravenous immune globulin therapy in hypogammaglobulinemia. A review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

Comparison of high-dose and low-dose intravenous immunoglobulin therapy in patients with primary immunodeficiency diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

Half-life and clearance of pH 6.8 and pH 4.25 immunoglobulin G intravenous preparations in patients with primary disorders of humoral immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

Intravenous immune globulins. A review of their uses in selected immunodeficiency and autoimmune diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

The use and mechanisms of action of intravenous immunoglobulin: an update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

Correlation of in vitro antibody synthesis with the outcome of intravenous gamma-globulin treatment of chronic idiopathic thrombocytopenic purpura

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

Intravenous immunoglobulin therapy for the antiphospholipid syndrome in pregnancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

Anti-idiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

Suppressor cell function after intravenous gammaglobulin treatment in adult chronic idiopathic thrombocytopenic purpura

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

Network theory in autoimmunity. In vitro suppression of serum anti-DNA antibody binding to DNA by anti-idiotypic antibody in systemic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

7 January 2021

Human IgG Fc receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

Anti-idiotypic immunity and autoimmunity. I. In vitro and in vivo effects of anti-idiotypic antibodies to spontaneously occurring autoantibodies to rat thyroglobulin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

Peripheral K lymphocytes in autoimmune thyroid disease: decrease in Graves' disease and increase in Hashimoto's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

Effect of intravenous immune globulin on natural killer cell activity: possible association with autoimmune neutropenia and idiopathic thrombocytopenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

Safety and patient acceptability of intravenous immune globulin in 10% maltose

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

Hemolysis following intravenous immune globulin therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

Fatal thrombotic events during treatment of autoimmune thrombocytopenia with intravenous immunoglobulin in elderly patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

Thrombotic events after intravenous immunoglobulin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

Inactivation and partition of human T-cell lymphotrophic virus, type III, during ethanol fractionation of plasma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

Antibody against the human immunodeficiency virus in commercial intravenous gammaglobulin preparations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

HTLV-III antibody in commercial immunoglobulin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

Passive transfer of antibodies to human T-cell lymphotropic virus type III in patients receiving high-dose intravenous immunoglobulin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

Transmission of viral infections through intravenous immune globulin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

The Anatomical Relations of Hypertrophy of the Cervix Uteri

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

Autoantibodies in chronic ITP.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

Chronic idiopathic thrombocytopenic purpura

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

The prenatal prediction of thrombocytopenia in infants of mothers with clinically diagnosed immune thrombocytopenia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

Immune thrombocytopenic purpura and pregnancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

Maternal thrombocytopenia in pregnancy: time for a reassessment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

High-dose intravenous IgG in adults with autoimmune thrombocytopenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

Intravenous immunoglobulin (i.v. IgG) for previously treated acute or for chronic idiopathic thrombocytopenic purpura (ITP) in childhood: a prospective multicenter study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

High-dose intravenous immunoglobulin therapy in patients with immune thrombocytopenic purpura

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

Management of immune thrombocytopenia in pregnancy: response to infusions of immunoglobulins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

Intravenous IgG for autoimmune thrombocytopenia in pregnancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

Idiopathic thrombocytopenic purpura in pregnancy and neonatal period

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

High-dose intravenous IgG in the management of pregnancy in women with idiopathic thrombocytopenic purpura

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

A new approach to idiopathic thrombocytopenic purpura during pregnancy by high-dose immunoglobulin G infusion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

Immune thrombocytopenia: effects of maternal gamma globulin infusion on maternal and fetal serum, platelet, and monocyte IgG.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

Intravenous treatment with gammaglobulin in adults with immune thrombocytopenic purpura: review of the literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

Mechanisms of thrombocytopenia in chronic autoimmune thrombocytopenic purpura. Evidence of both impaired platelet production and increased platelet clearance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

Detection of Splenic Anti-Platelet Antibody Synthesis in Idiopathic Autoimmune Thrombocytopenic Purpura (ATP)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

Possible mechanisms of intravenous immunoglobulin treatment in childhood idiopathic thrombocytopenic purpura (ITP).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

Treatment of refractory immune thrombocytopenic purpura with an anti-Fc gamma-receptor antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

Platelet counts in infants of women with autoimmune thrombocytopenia: effects of steroid administration to the mother

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

Fetal platelet counts in thrombocytopenic pregnancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

Syndrome of the black swan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

Lupus anticoagulant, thrombosis, and fetal loss

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

Obstetric complications associated with the lupus anticoagulant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

Decidual vasculopathy and extensive placental infarction in a patient with repeated thromboembolic accidents, recurrent fetal loss, and a lupus anticoagulant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

Repeated fetal losses associated with antiphospholipid antibodies: a collaborative randomized trial comparing prednisone with low-dose heparin treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

Antibody to cardiolipin as a predictor of fetal distress or death in pregnant patients with systemic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

Fetal survival after prednisone suppression of maternal lupus-anticoagulant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

Prevention of anticardiolipin antibody-related pregnancy losses with prednisone and aspirin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

Lupus anticoagulant in pregnancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

SLE anticoagulant: transient inhibition by high dose immunoglobulin infusions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

Intravenous gammaglobulin, antiphospholipid antibodies, and thrombocytopenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

Lupus anticoagulant and recurrent fetal loss: successful treatment with gammaglobulin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

Repeated fetal losses and the lupus anticoagulant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

Intravenous immunoglobulin treatment of pregnant patients with recurrent pregnancy loss caused by antiphospholipid antibodies and Rh immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

Intravenous gamma-globulin, antiphospholipid antibodies, and pregnancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

Successful treatment in two women with antiphospholipid antibodies and refractory pregnancy losses with intravenous immunoglobulin infusions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

Intravenous immunoglobulin treatment of pregnant patients with recurrent pregnancy losses associated with antiphospholipid antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

Normal fetal growth in women with antiphospholipid syndrome treated with high-dose intravenous immunoglobulin (IVIG)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

Immunoglobulin G fractions from patients with antiphospholipid antibodies cause fetal death in BALB/c mice: a model for autoimmune fetal loss

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

Induction of anti-phospholipid syndrome in naive mice with mouse lupus monoclonal and human polyclonal anti-cardiolipin antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

The effect of intravenous gamma-globulin on the induction of experimental antiphospholipid syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

Clinical importance of persistence of anticardiolipin antibodies in systemic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

Alloimmunization to the PlA1 platelet antigen: results of a prospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

348 cases of suspected neonatal alloimmune thrombocytopenia

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

7 January 2021

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

7 January 2021

Management of alloimmune neonatal and antenatal thrombocytopenia

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

Continuing controversy in alloimmune thrombocytopenia: fetal hyperimmunoglobulinemia fails to prevent thrombocytopenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

Neonatal alloimmune thrombopenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

Antenatal treatment of neonatal alloimmune thrombocytopenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

Management of fetal alloimmune thrombocytopenia by weekly in utero platelet transfusions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

Failure of antenatal high-dose immunoglobulin to improve fetal platelet count in neonatal allo-immune thrombocytopenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

Antenatal management of alloimmune thrombocytopenia with intravenous γ-globulin: A randomized trial of the addition of low-dose steroid to intravenous γ-globulin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

Very early intracranial haemorrhage in alloimmune fetal thrombocytopenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

Rhesus haemolytic disease treated with high-dose intravenous immunoglobulin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

High-dose intravenous immunoglobulin as the sole prenatal treatment for severe Rh immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

High-dose intravenous IgG for the treatment of severe rhesus alloimmunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

Use of intravenously administered immune globulin to prevent nosocomial sepsis in low birth weight infants: report of a pilot study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

Inefficacy of intravenous immunoglobulin in patients with low-risk thrombotic thrombocytopenic purpura/hemolytic-uremic syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

Idiopathic thrombocytopenic purpura in pregnancy: a randomized trial on the effect of antenatal low dose corticosteroids on neonatal platelet count

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

7 January 2021

In utero cerebral hemorrhage in alloimmune thrombocytopenia

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

7 January 2021

Antenatal management of fetal alloimmune and autoimmune thrombocytopenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

7 January 2021

High-dose immunoglobulin in the antenatal treatment of neonatal alloimmune thrombocytopenia: case report and review

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

7 January 2021

Intravenous immunoglobulin for prevention of sepsis in preterm and low birth weight infants

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2980043-9

7 January 2021

10.1016/S0002-9378(97)80043-9

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9024121%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

1 reference